



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2854798 A1 2004/02/26

(21) **2 854 798**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(22) Date de dépôt/Filing Date: 2003/08/15

(41) Mise à la disp. pub./Open to Public Insp.: 2004/02/26

(62) Demande originale/Original Application: 2 494 756

(30) Priorité/Priority: 2002/08/16 (US10/222,140)

(51) Cl.Int./Int.Cl. *A61K 47/34* (2006.01),
A61K 39/395 (2006.01), *A61K 47/10* (2006.01),
A61K 47/22 (2006.01), *A61K 9/08* (2006.01)

(71) Demandeur/Applicant:
ABBVIE BIOTECHNOLOGY LTD., BM

(72) Inventeurs/Inventors:
KRAUSE, HANS-JUERGEN, DE;
BAUST, LISA, DE;
DICKES, MICHAEL, DE

(74) Agent: TORYS LLP

(54) Titre : ANTICORPS ANTI-TNF ALPHA EN SOLUTION ET LEURS UTILISATIONS

(54) Title: ANTI-TNF-ALPHA ANTIBODIES IN SOLUTION AND USES THEREOF

(57) **Abrégé/Abstract:**

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.



ABSTRACT

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __2__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __2__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

SEQUENCE LISTING

<110> AbbVie Biotechnology Ltd.

<120> ANTI-TNF-ALPHA ANTIBODIES IN SOLUTION AND USES THEREOF

<130> 36656-2277

<140> Divisional of CA2,494,756

<141> 2003-08-15

<150> US10/222,140

<151> 2002-08-16

<160> 34

<170> PatentIn version 3.5

<210> 1

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> Mutated human antibody

<400> 1

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	

Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Arg	Asn	Tyr
			20					25					30		

Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
		35					40					45			

Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				

Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75				80	

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 2
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>
 <223> Mutated human antibody

<400> 2
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
 50 55 60

Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
 <223> Mutated human antibody

<220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> Thr or Ala

<400> 3
 Gln Arg Tyr Asn Arg Ala Pro Tyr Xaa
 1 5

<210> 4
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
 <223> Mutated human antibody

<220>
 <221> MOD_RES
 <222> (12)..(12)
 <223> Tyr or Asn

<400> 4
 Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Xaa
 1 5 10

<210> 5
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 5

Ala Ala Ser Thr Leu Gln Ser

1

5

<210> 6

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 6

Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu

1

5

10

15

Gly

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 7

Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala

1

5

10

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 8

Asp Tyr Ala Met His
1 5

<210> 9

<400> 9
000

<210> 10

<400> 10
000

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 11

Gln Lys Tyr Asn Ser Ala Pro Tyr Ala
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 12

Gln Lys Tyr Asn Arg Ala Pro Tyr Ala
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 13

Gln Lys Tyr Gln Arg Ala Pro Tyr Thr
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 14

Gln Lys Tyr Ser Ser Ala Pro Tyr Thr
1 5

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 15

Gln Lys Tyr Asn Ser Ala Pro Tyr Thr
1 5

<210> 16

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 16

Gln Lys Tyr Asn Arg Ala Pro Tyr Thr
1 5

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 17

Gln Lys Tyr Asn Ser Ala Pro Tyr Tyr
1 5

<210> 18

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 18

Gln Lys Tyr Asn Ser Ala Pro Tyr Asn
1 5

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 19

Gln Lys Tyr Thr Ser Ala Pro Tyr Thr
1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 20

Gln Lys Tyr Asn Arg Ala Pro Tyr Asn
1 5

<210> 21

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 21

Gln Lys Tyr Asn Ser Ala Ala Tyr Ser
1 5

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 22

Gln Gln Tyr Asn Ser Ala Pro Asp Thr
1 5

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 23

Gln Lys Tyr Asn Ser Asp Pro Tyr Thr
1 5

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 24

Gln Lys Tyr Ile Ser Ala Pro Tyr Thr
1 5

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 25

Gln Lys Tyr Asn Arg Pro Pro Tyr Thr
1 5

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 26

Gln Arg Tyr Asn Arg Ala Pro Tyr Ala
1 5

<210> 27

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> Mutated human antibody

<400> 27

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Ser	Ser	Leu	Asp	Asn
1				5					10		

<210> 28

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 28

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Ser	Ser	Leu	Asp	Lys
1				5					10		

<210> 29

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 29

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Ser	Ser	Leu	Asp	Tyr
1				5					10		

<210> 30

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 30

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Ser	Ser	Leu	Asp	Asp
1				5					10		

<210> 31

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 31

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Phe	Ser	Leu	Asp	Tyr
1				5					10		

<210> 32

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 32

Ala	Ser	Tyr	Leu	Ser	Thr	Ser	Ser	Ser	Leu	His	Tyr
1				5					10		

<210> 33

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 33

Ala	Ser	Phe	Leu	Ser	Thr	Ser	Ser	Ser	Leu	Glu	Tyr
1				5					10		

<210> 34

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> Mutated human antibody

<400> 34

Ala	Ser	Tyr	Leu	Ser	Thr	Ala	Ser	Ser	Leu	Glu	Tyr
1				5					10		

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __2__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __2__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

CLAIMS

We claim:

1. A liquid aqueous pharmaceutical formulation comprising a human anti-Tumor Necrosis Factor alpha (TNF α) IgG antibody, or an antigen-binding portion thereof, at a concentration from 20 to 150 mg/ml, a polyol, a polysorbate at a concentration from 0.1 to 10 mg/ml, and a buffer system comprising histidine,

wherein said formulation has a pH from 4 to 8, and

wherein the antibody comprises a light chain variable region and a heavy chain variable region of antibody D2E7.